Mitomycin C treatment of advanced, hormone-resistant prostatic carcinoma: a phase II study

A. Veronesi, V. Dal Bo, G. Lo Re, M. Della Valentina, U. Tirelli, A. Merlo, R. Talamini, M. Francini, S. Monfardini

Research output: Contribution to journalArticle

Abstract

From February 1984 to February 1987, 29 patients with advanced, hormone-resistant prostatic carcinoma were treated with mitomycin-C at a dose of 20 mg/m2 every 6 weeks (15 mg/m2 in patients >75 years old and in those who had undergone previous radiotherapy). In the 27 evaluable patients, there were no complete remissions (CR), 2 partial remissions (PR), 14 stabilizations (STAB), and 11 cases of progressive disease (PRO). Ten stabilized patients showed significant pain reduction. Toxicity was minimal. The actuarial median survival was 10.8 months. In this study, mitomycin C was not active in terms of CR+PR; however, a beneficial symptomatic effect was frequently observed.

Original languageEnglish
Pages (from-to)115-116
Number of pages2
JournalCancer Chemotherapy and Pharmacology
Volume23
Issue number2
DOIs
Publication statusPublished - Feb 1989

    Fingerprint

ASJC Scopus subject areas

  • Pharmacology
  • Oncology
  • Cancer Research

Cite this

Veronesi, A., Bo, V. D., Re, G. L., Valentina, M. D., Tirelli, U., Merlo, A., Talamini, R., Francini, M., & Monfardini, S. (1989). Mitomycin C treatment of advanced, hormone-resistant prostatic carcinoma: a phase II study. Cancer Chemotherapy and Pharmacology, 23(2), 115-116. https://doi.org/10.1007/BF00273528